Mirna Therapeutics Inc. (NASDAQ:MIRN) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday.

According to Zacks, “Mirna Therapeutics, Inc. is a biopharmaceutical company which develops microRNA-based oncology therapeutics. The Company’s pipeline products include MRX34, miR-Rxlet-7, miR-Rx06, miR-Rx07 and miR-Rx16 which are in preclinical trials. Its lead product, MRX34, is a liposome-encapsulated miR-34 mimic indicated for the treatment of primary liver cancer, solid cancers with liver metastases and hematological malignancies. Mirna Therapeutics, Inc. is headquartered in Austin, Texas. “

MIRN has been the subject of a number of other research reports. HC Wainwright downgraded Mirna Therapeutics from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $6.00 to $2.00 in a report on Friday, September 23rd. Leerink Swann downgraded Mirna Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $10.00 to $4.00 in a report on Monday, August 15th. Oppenheimer Holdings Inc. downgraded Mirna Therapeutics from an “outperform” rating to a “market perform” rating in a report on Wednesday, September 21st. Citigroup Inc. decreased their price objective on Mirna Therapeutics from $4.50 to $2.00 and set a “neutral” rating for the company in a report on Thursday, September 22nd. Finally, Cantor Fitzgerald downgraded Mirna Therapeutics from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $14.00 to $2.00 in a report on Wednesday, September 21st. Six investment analysts have rated the stock with a hold rating, The stock presently has an average rating of “Hold” and an average target price of $3.88.

Analyst Recommendations for Mirna Therapeutics (NASDAQ:MIRN)

Shares of Mirna Therapeutics (NASDAQ:MIRN) opened at 1.21 on Tuesday. The firm’s 50-day moving average is $1.58 and its 200 day moving average is $3.30. Mirna Therapeutics has a 52-week low of $1.12 and a 52-week high of $11.01. The company’s market capitalization is $25.21 million.

Mirna Therapeutics Company Profile

Mirna Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response.

5 Day Chart for NASDAQ:MIRN

Receive News & Stock Ratings for Mirna Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc. and related stocks with our FREE daily email newsletter.